| Title |
Olodaterol: First Global Approval
|
|---|---|
| Published in |
Drugs, October 2013
|
| DOI | 10.1007/s40265-013-0137-9 |
| Pubmed ID | |
| Authors |
Andrew Gibb, Lily P. H. Yang |
| Abstract |
Olodaterol (Striverdi(®) Respimat(®)) is a novel, long-acting, β2-adrenergic receptor agonist developed by Boehringer Ingelheim for the treatment of chronic obstructive pulmonary disease (COPD). The drug is delivered via the Respimat(®) Soft Mist™ inhaler. Olodaterol received its first global approval for the once-daily maintenance treatment of COPD in Canada and Russia, and submissions for regulatory approval have also been made in the USA, the EU and elsewhere. Phase II trials have been conducted in patients with asthma. The company is also developing a fixed-dose combination of olodaterol with tiotropium bromide, a long-acting anti-muscarinic agent, for the treatment of COPD. This article summarizes the milestones in the development of olodaterol leading to this first approval for COPD. |
X Demographics
The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 8% |
| Argentina | 1 | 8% |
| New Zealand | 1 | 8% |
| Kuwait | 1 | 8% |
| Ecuador | 1 | 8% |
| Unknown | 8 | 62% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 11 | 85% |
| Science communicators (journalists, bloggers, editors) | 1 | 8% |
| Scientists | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 3% |
| Romania | 1 | 3% |
| Brazil | 1 | 3% |
| Unknown | 33 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 4 | 11% |
| Student > Master | 4 | 11% |
| Other | 3 | 8% |
| Student > Bachelor | 3 | 8% |
| Student > Postgraduate | 3 | 8% |
| Other | 11 | 31% |
| Unknown | 8 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 42% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 19% |
| Nursing and Health Professions | 2 | 6% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Social Sciences | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 9 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 June 2014.
All research outputs
#4,115,980
of 22,727,570 outputs
Outputs from Drugs
#579
of 3,251 outputs
Outputs of similar age
#38,824
of 212,193 outputs
Outputs of similar age from Drugs
#3
of 36 outputs
Altmetric has tracked 22,727,570 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,251 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 212,193 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 36 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.